BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, January 9, 2025
See today's BioWorld Asia
Home
» Hua exploits in-licensing opportunities, focuses on unmet needs in China
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Hua exploits in-licensing opportunities, focuses on unmet needs in China
Jan. 2, 2014
By
Shannon Ellis
No Comments
SHANGHAI – In 2011 Shanghai-based Hua Medicine Ltd. made headlines in China as a start-up R&D biotech flush with a $50 million commitment from venture capital investors and a crew of talented veterans as founders and board members.
BioWorld Asia